Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Calvert

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
Lancet (London, England)|September 3, 1988
Carboplatin or cisplatin?A H Calvert, A Horwich, E S Newlands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusionI Rafi, G A Taylor, J A Calvete, et al.
British Journal of Cancer|September 1, 1999
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein bindingN J Curtin, K J Bowman, R N Turner, et al.
Journal of Medicinal Chemistry|November 7, 2000
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeraseA W White, R Almassy, A H Calvert, et al.
Journal of Medicinal Chemistry|May 1, 1991
Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modificationsP R Marsham, L R Hughes, A L Jackman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialL Biganzoli, T Cufer, P Bruning, et al.
Seminars in Oncology|October 1, 1994
Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation studyA H Calvert, M J Lind, S Ghazal-Aswad, et al.
Journal of Medicinal Chemistry|November 1, 1990
Quinazoline antifolate thymidylate synthase inhibitors: benzoyl ring modifications in the C2-methyl seriesP R Marsham, A L Jackman, J Oldfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1993
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study GroupD R Newell, A D Pearson, K Balmanno, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Lancet (London, England)|September 3, 1988
Carboplatin or cisplatin?A H Calvert, A Horwich, E S Newlands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell linesC A Delaney, L Z Wang, S Kyle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 1995
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusionI Rafi, G A Taylor, J A Calvete, et al.
British Journal of Cancer|September 1, 1999
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein bindingN J Curtin, K J Bowman, R N Turner, et al.
Journal of Medicinal Chemistry|November 7, 2000
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeraseA W White, R Almassy, A H Calvert, et al.
Journal of Medicinal Chemistry|May 1, 1991
Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modificationsP R Marsham, L R Hughes, A L Jackman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2002
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III TrialL Biganzoli, T Cufer, P Bruning, et al.
Seminars in Oncology|October 1, 1994
Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation studyA H Calvert, M J Lind, S Ghazal-Aswad, et al.
Journal of Medicinal Chemistry|November 1, 1990
Quinazoline antifolate thymidylate synthase inhibitors: benzoyl ring modifications in the C2-methyl seriesP R Marsham, A L Jackman, J Oldfield, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1993
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study GroupD R Newell, A D Pearson, K Balmanno, et al.
Pageof 15